Improvement of Visual Performance With Intravitreal Administration of 9-cis-Retinal in Rpe65-Mutant Dogs
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the efficacy of intravitreal administration of 9-cis-retinal in restoring visual function in Rpe65-mutant dogs. METHODS: Intravitreal injection of 9-cis-retinal was administered in 1 eye of 7 Rpe65-/- dogs at a range of ages. Electroretinogram analysis and testing of visual performance was used to evaluate outcomes after a single injection and in 2 dogs after a second injection in the same eye. RESULTS: In 5 of 7 injected dogs, 9-cis-retinal injection resulted in increased rod electroretinogram responses and improved functional vision. Three injected dogs exhibited increased 33-Hz flicker amplitudes characteristic of cone-mediated responses. Electroretinogram improvement was no longer evident by week 10 postinjection in 1 dog monitored over time. A second injection of 9-cis-retinal was performed in the same eye of 2 of the 7 dogs and also resulted in rescue of visual function. CONCLUSION: Our findings establish that 9-cis-retinoid therapy can restore visual function in a canine model of human disease resulting from RPE65 mutations. CLINICAL RELEVANCE: These positive proof-of-principle results provide support for the development of intravitreal devices for sustained delivery of 9-cis-retinal as a therapy for conditions resulting from failure of the visual cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“The lack of ERG at this intensity is similar to that reported by others.(5) Vision testing correlated with the recovery of darkadapted ERG responses.”
ResultHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929 · cited 1×
“Disruption of the Rpe65 gene in knockout mice results in a lack of 11cis-retinal and electroretinogram (ERG) responses, downregulation of rhodopsin protein, and accumulation of retinyl esters in the retinal pigment epithelium.(3) Groundbreaking research demonstrating the efficacy of gene therapy for inherited retinal…”
BackgroundHanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350 · cited 1×
“Mutations in RPE65 are responsible for approximately 6% of autosomal recessive Leber congenital amaurosis, often referred to as Leber congenital amaurosis type 2, with patients progressing to legal blindness in early adulthood.(2)”
BackgroundYamamoto, H., Simon, A., Eriksson, U., Harris, E., Berson, E. L., & Dryja, T. P. (1999) · Nature Genetics · doi:10.1038/9707 · Cited by 298
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252 · cited 2×
“As an alternative approach, studies with Rpe65 knockout mice have shown that retinoid supplementation strategies involving oral delivery of 9-cis-retinal, and intraperitoneal injection of 11-cis-retinal, are effective in reconstituting active visual pigments and visual responses.(12,13) Furthermore, a combination of r…”
BackgroundResultRecovery of Visual Functions in a Mouse Model of Leber Congenital Amaurosis
Van Hooser, J. P., Liang, Y., Maeda, T., Kuksa, V., Jang, G.-F., He, Y.-G., Rieke, F., Fong, H. K. W., Detwiler, P. B., & Palczewski, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112384200 · Cited by 154 · cited 1×
“6 to 16 10(4) μg/kg of body weight.(13,23) Electroretinogram analysis of Rpe65-mutant dogs treated with 9-cis-retinal showed increased darkadapted ERG amplitudes in 5 of 7 treated dogs and cone flicker responses in 3 of 7 treated dogs.”
BackgroundZnoiko, S. L., Rohrer, B., Lu, K., Lohr, H. R., Crouch, R. K., & Ma, J.-X. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0653 · Cited by 146 · cited 1×
“This observation is noteworthy in the context of previous studies showing that cone cell death begins in Rpe65−/− mice at a few weeks of age.(30,31) Early cone cell death is also evident by in vivo imaging of patients with RPE65-null mutations, including young children(32-34); however, a subpopulation of cone cells ap…”
ResultBatten, M. L., Imanishi, Y., Tu, D. C., Doan, T., Zhu, L., Pang, J., Glushakova, L., Moise, A. R., Baehr, W., Van Gelder, R. N., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020333 · Cited by 134 · cited 1×
“with a failure of the visual cycle due to a lack of lecithin retinol acyltransferase.(14) Oral retinoid therapy has entered phase 1b clinical trials, with early reports suggesting evidence of efficacy in patients with lecithin retinol acyltransferasemutations.”
Cone Opsin Mislocalization in Rpe65−/−Mice: A Defect That Can Be Corrected by 11-cis Retinal
Rohrer, B., Lohr, H. R., Humphries, P., Redmond, T. M., Seeliger, M. W., & Crouch, R. K. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0533 · Cited by 133
Barriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
Effects of Long-Term Administration of 9-cis-Retinyl Acetate on Visual Function in Mice
Maeda, T., Maeda, A., Leahy, P., Saperstein, D. A., & Palczewski, K. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2301 · Cited by 27
Cited by
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
Self-citationMowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Koenekoop, R. K., Sui, R., Sallum, J., van den Born, L. I., Ajlan, R., Khan, A., den Hollander, A. I., Cremers, F. P. M., Mendola, J. D., Bittner, A. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60153-7 · Cited by 103
Vitamin A derivatives as treatment options for retinal degenerative diseases
Perusek, L., & Maeda, T. (2013) · Nutrients · doi:10.3390/nu5072646 · Cited by 60
“Early in life patients with LCA exhibit visual impairment with attenuated rod and cone function, macular atrophy, severely delayed or minimal ERG responses, nystagmus, and retinal cell degeneration [83,84,87,88].”
BackgroundInfluentialDev Borman, A., Ocaka, L. A., Mackay, D. S., Ripamonti, C., Henderson, R. H., Moradi, P., Hall, G., Black, G. C., Robson, A. G., Holder, G. E., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9548 · Cited by 44
Metadata
- Authors
- Gearhart, P. M.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-11-08
- Volume
- 128
- Issue
- 11
- Pages
- 1442
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2021632320
- Cited by
- 52
- References
- 14
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.